PTTG3P and neoplasm: PTTG3P in patients with lung adenocarcinoma (LUAD) is connected with shortening the metaphase to anaphase transition in mitosis, increasing cell viability after cisplatin or paclitaxel treatment, and facilitating tumor growth.